Sheela Upadhyaya | Associate Director Highly Specialised Technologies
National Institute For Health and Care Excellence

Sheela Upadhyaya, Associate Director Highly Specialised Technologies, National Institute For Health and Care Excellence

Sheela Upadhyaya is currently the Associate Director of the Highly Specialised Technology program at NICE and is responsible for running the program to evaluate medicines and technologies for rare and ultra-rare conditions for commissioning in the NHS.

Prior to joining NICE, she was responsible for commissioning rare and ultra-orphan disease services in NHS England, where she delivered many improvements to these services by collaborating with industry, clinicians and patient groups. She held the position of national lead for lysosomal storage disorders and the Extra Corporeal Membrane (ECMO) service for adults working closely with ITU centres in England to manage bed pressures and patient needs.  In addition, she successfully decommissioned failing services and seamlessly transferred the care of patients to better quality services.

As commissioner for the National Specialised Commissioning team, she held responsibility for the genetics and metabolic portfolio leading nationally for lysosomal storage disorders.  In this role she delivered more efficient drug and homecare prices by running national tender exercises with the Department of Health, Commercial Medicines Unit.  As a result of this, she was selected to sit on the Department of Health’s National Homecare Medicines Committee developing the national homecare standards. Sheela has a passion for partnership working believes that collaboration across the sector is the key to delivering high quality results. Mrs Upadhyaya was nominated for a “Compact Award” in recognition of her patient engagement activity. She strives to ensure services for patients with rare conditions provide excellent quality and good outcomes in an efficient effective environment.

Appearances:



Pre-congress Workshops Nov 6 @ 14:01

Workshop D (2pm-5pm): Managed Access…Are they the holy grail?

  • How will the development of the EUnetHTA initiative support the managed entry agreement development and data collection, can it become a joint European venture too?
  • Success stories and learning from a variety of jurisdictions, discuss best practices from multiple perspectives and provide a hands-on opportunity to craft MEAs for specific therapies
last published: 16/Oct/18 13:35 GMT

back to speakers

Follow us on

 

Sign Up for Event Updates

Get Involved At World Orphan Drug Congress 2018

 

To Sponsor Or Exhibit

 

Andrew Mears
andrew.mears@terrapinn.com
t/ +44 20 7092 1228

 

To Speak

 

Wing-Yun Cheung
wing-yun.cheung@terrapinn.com
t/ +44 20 7092 1172

 

To Register

 

Issa Mauthoor
issa.mauthoor@terrapinn.com
t/ +44 20 7092 1257